SWM
MRVI icon

SeaCrest Wealth Management’s Maravai LifeSciences MRVI Stock Holding History

SeaCrest Wealth Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,125
Closed -$32K – 1151
2022
Q2 		$32K Buy
+1,125
New +$35.6K ﹤0.01% 1304

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

SeaCrest Wealth Management's MRVI Position: Q3 2022 in Review

SeaCrest Wealth Management sold out of Maravai LifeSciences (MRVI) in Q3 2022, closing a stake of 1,125 shares — an estimated $32K sold.

SeaCrest Wealth Management first reported a position in MRVI in Q2 2022 and held it in 1 quarter. The position peaked at $32K in Q2 2022. 202 funds tracked by Wall St. Rank hold MRVI as of Q3 2022.

  • SeaCrest Wealth Management reported no remaining Maravai LifeSciences position as of Q3 2022 after selling out during the quarter.
  • SeaCrest Wealth Management sold 1,125 Maravai LifeSciences shares in Q3 2022, an estimated $32K.
  • SeaCrest Wealth Management first reported a position in Maravai LifeSciences in Q2 2022 and held it in 1 quarter.
  • SeaCrest Wealth Management's Maravai LifeSciences position peaked at $32K in Q2 2022.
  • 202 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2022.

Based on SeaCrest Wealth Management's 13F filing for Q3 2022, filed 15 Nov 2022.